Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Payables (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Payables data on record, last reported at $1.7 million in Q3 2025.

  • For Q3 2025, Payables rose 26.07% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, up 26.07%, while the annual FY2024 figure was $585000.0, 26.9% up from the prior year.
  • Payables reached $1.7 million in Q3 2025 per ASMB's latest filing, up from $743000.0 in the prior quarter.
  • Across five years, Payables topped out at $3.6 million in Q1 2021 and bottomed at $461000.0 in Q4 2023.
  • Average Payables over 5 years is $1.6 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Payables: crashed 81.51% in 2023, then soared 76.12% in 2024.
  • A 5-year view of Payables shows it stood at $2.7 million in 2021, then fell by 6.24% to $2.5 million in 2022, then plummeted by 81.51% to $461000.0 in 2023, then rose by 26.9% to $585000.0 in 2024, then soared by 187.69% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $1.7 million in Q3 2025, $743000.0 in Q2 2025, and $875000.0 in Q1 2025.